



## Press Release

### **MSN Labs launches a new drug for percutaneous coronary intervention.**

- *A bioequivalent generic, **CANREAL™** injection (Cangrelor) is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor*

**Hyderabad, 01 October 2021:** MSN Laboratories, one of country's leading, fully integrated research-based Pharmaceutical organizations with expertise spanning across the domains of APIs, Finished Dosages and Branded Generics (Prescription Medicines) became the first company to launch the generic **CANREAL™** injection (Cangrelor) in India.

The bioequivalent generic **CANREAL™** (Cangrelor) is the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition developed to overcome both delayed and prolonged anti platelet activity. The drug was approved by DCGI (Drug Controller General of India) recognizing the unmet need for intravenous rapidly acting, reversible antiplatelet agent in the country. It is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor

The launch of the Canreal coincided with a mega cardiologist scientific meeting organized by MSN Labs, which was addressed by Dr Deepak Bhatt Professor, Harvard Medical, USA also leading investigator for international trials done on Cangrelor. A close to thousand leading cardiologists pan India attended and shared their views on "Antiplatelet therapy featuring Canreal (Cangrelor)". Eminent key opinion leaders appreciated the efforts of MSN Labs in introducing the Canreal at an affordable cost compared to International markets for Indian patients.

MSN Group commented: "This launch signifies MSN Labs' commitment to bring access to new, affordable and diverse therapeutic options, swiftly and consistently, for helping the world overcome life-threatening diseases. **The organization is hopeful that this drug will prove to be highly advantageous for both patients and medical fraternity in terms of treatment outcomes, safety and efficacy.**"

The product which comes in a single-use 10 mL vial containing 50 mg Cangrelor as a lyophilized powder for reconstitution, is manufactured at FDA and EU approved state-of-the-art injectable facility in Hyderabad. It is available at all retail/hospital attached pharmaceutical outlets and is dispensed upon a prescription by a cardiologist.

**For more information and availability **CANREAL™** (Cangrelor) reach out to [customercare@msnlabs.com](mailto:customercare@msnlabs.com).**

\*\*\*END\*\*\*

**About MSN Group:**

MSN Group is the fastest growing research-based and fully integrated pharmaceutical company headquartered in Hyderabad, India. Founded in 2003 with a mission to make healthcare affordable, MSN has nine API and five finished dosage facilities in India & USA. The Group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals. With its core focus on speed and consistency in delivery, MSN has achieved more than 650 national and international patents, over 130 ANDAs, and emerged as world no. 1 in active US DMF filings. The company, with a product portfolio of 450+ APIs and 300+ formulations spanning 35 major therapies, has won the trust of more than 40 million patients in 65 countries across the world.

*For information on MSN Labs, please visit [www.msnlabs.com](http://www.msnlabs.com)*

**MSN Labs Media Contact:**

PVR Surya Kanth

Corporate Communications

Mobile: +91 8790829841

E-mail: [pvr.suryakanth@msnlabs.com](mailto:pvr.suryakanth@msnlabs.com)